Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13121MR)

This product GTTS-WQ13121MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13121MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5404MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ10420MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ8058MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ10682MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ9317MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ15382MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ1444MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ10328MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LJM716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW